Diuretics 2011.10.19 R3 주혜영. Introduction  among the most commonly used drugs  diminish sodium reabsorption at different sites in the nephron → increase.

Slides:



Advertisements
Similar presentations
Chapter 51 Diuretic Agents
Advertisements

Diuretics Clinical Conditions Requiring Diuretic Therapy:
THIAZIDE DIURETICS Secreted into the tubular lumen by the organic acid transport mechanisms in the proximal tubule Act on the distal tubule to inhibit.
Diuretics. A. Kidney functions Kidneys have a number of essential functions:
Chapter 41 Diuretics 1.
Diuretics and Dehydrants. §1 Diuretics Abnormalities in fluid volume and electrolyte composition are common and important clinical problems. Drugs that.
DIURETICS. Functions of the kidneys Volume Acid-base balance Osmotic pressure Electrolyte concentration Excretion of metabolites and toxic substances.
Diuretics A diuretic is a substance that increases the rate of urine volume output Most diuretics also increase urinary excretion of solutes, especially.
Diuretics. Why do we want to know about diuretics? What do kidneys do? What can go wrong? Interventions that can be used how do they work? Effects, side.
Excretion of Water and Electrolytes
BIMM118 Renal Pharmacology Diuretics: Carbonic Anhydrase Inhibitors Thiazides Loop Diuretics Potassium-sparing Diuretics.
DIURETICS Brogan Spencer and Laura Smitherman. What is a diuretic? Substance that promotes the formation (excretion) of urine.
Control of Renal Function. Learning Objectives Know the effects of aldosterone, angiotensin II and antidiuretic hormone on kidney function. Understand.
Role of Kidneys In Regulation Of Potassium Levels In ECF
Diuretics Chris Hague, PhD
DIURETICS By: Prof. A. Alhaider.
DPT IPMR KMU Dr. Rida Shabbir.  K+ extracellular 4.2 mEq/L  Increase in conc to 3-4 mEq/L causes cardiac arrhythmias causing cardiac arrest and fibrilation.
Diuretics. From Knauf & Mutschler Klin. Wochenschr : % 20% 5% 4.5% 0.5% Volume 1.5 L/day Urine Na 100 mEq/L Na Excretion 155 mEq/day.
Diuretic Agents in Hypertension and other disorders
Prof. Hanan Hagar Pharmacology Department
Diuretics Remove sodium & water
DIURETIC DRUGS.
1-Overview 2-Classification 3-Indiviual drugs 1-Indications of Diuretics. 2-Adverse effects. 3-Mannitol and Carbonic Anhydrase inhibitors.
Lecture – 3 Dr. Zahoor 1. TUBULAR REABSORPTION  All plasma constituents are filtered in the glomeruli except plasma protein.  After filtration, essential.
Diuretics the role of different portions of the nephron in ion exchange; the sites of action and pharmacology of diuretics; the therapeutic applications.
BLOCK: URIN 313 PHYSIOLOGY OF THE URINARY SYSTEM LECTURE 3 1 Dr. Amel Eassawi.
CARBONIC ANHYDRASE INHIBITORS ACETAZOLAMIDE E It is a sulfonamide derivative. It is a sulfonamide derivative. noncompetitively but reversible inhibits.
DIURETICS Part 1 Prof. Hanan Hagar Pharmacology Unit.
Tubular reabsorption is a highly selective process
CHAPTER © 2012 The McGraw-Hill Companies, Inc. All rights reserved. 25 Diuretics.
DIURETIC DRUGS (DR.Farooq Alam) DIURETIC DRUGS (DR.Farooq Alam)
DIURETICS Part 1 Prof. Hanan Hagar Pharmacology Department.
Prof. Hanan Hagar Pharmacology Department
DIURETICS Diuretics are drugs which increase the excretion of sodium and water from the body by an action on the kidney. Their primary effect is to decrease.
DR. MOHD NAZAM ANSARI.  Some of pathological conditions associated with retention of sodium and water in the body e.g. Congestive Heart failure, Pulmonary.
Clinical Use of Diuretics
Sodium Reabsorption, Diuretics, and Diet Vivek Bhalla, MD Division of Nephrology Stanford University School of Medicine September 14th, 2015.
Drugs Used for Diuresis Chapter 29 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Diuretic Agents.
Diuretics and Antihypertensives
DIURETICS How do they work? WHAT DO THEY DO? When do I use them? How do I use them?
Pharmacology – I [PHL 313] DiureticsDiuretics Dr. Hassan Madkhali Assistant Professor Department of Pharmacology E mail:
Mosby items and derived items © 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 21 Diuretic Agents.
DIURETICS By: Prof. A. Alhaider 1433 H. Anatomy and Physiology of Renal system ► Remember the nephron is the most important part of the kidney which regulates.
Diuretic Agents.
Sodium Reabsorption, Diuretics, and Diet Vivek Bhalla, MD Division of Nephrology Stanford University School of Medicine September 14th, 2015.
Regulation of Potassium K+
DIURETICS By: Prof. A. Alhaider. Anatomy and Physiology of Renal system ► Remember the nephron is the most important part of the kidney that regulates.
What is high ceiling diuretic & Why?
Diuretics Clinical Conditions Requiring Diuretic Therapy: Cerebral Edema Cerebral Edema Pulmonary Edema Pulmonary Edema Hypertension Hypertension Congestive.
Diuretics (Saluretics). Diuretics increase urine excretion mainly by ↓ reabsorption of salts and water from kidney tubules These agents are ion transport.
MCQs from High yield areas of Diuretic Pharmacology
Diuretic Agents. Carbonic Anhydrase Inhibitors.
Osmotic diuretics Osmotic diuretics are pharmacologically inert substances (e.g. mannitol ) that are filtered in the glomerulus but not reabsorbed by the.
POTASSIUM-SPARING DIURETICS 1.Aldosterone antagonists: Spironolactone and eplerenone: The spironolactone-receptor complex is inactive complex results in.
Maintaining Water-Salt/Acid-Base Balances and The Effects of Hormones
Renal mechanisms for control ECF
Sodium Channel Inhibitors
(Furosemide, Ethacrynic acid, Bumetanide and Torsemide) DIURETICS: LOOP DIURETICS (Furosemide, Ethacrynic acid, Bumetanide and Torsemide)
Loop diuretics Domina Petric, MD.
D. C. Mikulecky Faculty Mentoring Program Virginia Commonwealth Univ.
Carbonic anhydrase inhibitors
Clinical pharmacology of diuretic agents
Potassium-sparing diuretics
Domina Petric, MD Aquaretics.
Thiazides Domina Petric, MD.
Sodium Homeostasis Sodium is an electrolyte of major importance in the human body. It is necessary for : normal extracellular volume dynamics  Na in ECF.
Diuretics By S.Bohlooli, PhD.
Diuretic Drugs.
REGULATION OF K,Ca, PHOSPHATE & MAGNISIUM
Presentation transcript:

Diuretics R3 주혜영

Introduction  among the most commonly used drugs  diminish sodium reabsorption at different sites in the nephron → increase urinary sodium and water losses → negative fluid balance  in the treatment of edematous states(heart failure, cirrhosis, nephrotic syndrome, renal failure), hypertension, electrolyte imbalance

N Engl J Med 2009;361:  Carbonic anhydrase inhibitor (acetazolamide) in proximal tubule  Loop diuretics in thick ascending limb of the loop of Henle  Thiazide-type diuretics in distal tubule  Potassium-sparing diuretics in cortical collecting tubule  Mannitol : osmotic diuresis mannitol

Acetazolamide  Carbonic anhydrase : plays an important role in proximal bicarbonate, sodium, and chloride reabsorption  Inhibits the activity of carbonic anhydrase → NaCl and NaHCO3 loss  The net diuresis is relatively modest  Most of the excess fluid delivered out of the proximal tubule is reclaimed in the more distal segments  The diuretic action is progressively attenuated by the metabolic acidosis that results from the loss of bicarbonate in the urine  edematous patients with metabolic alkalosis, hypercapnic chronic lung disease with metabolic alkalosis Harrison's Principles of Internal Medicine, 18th edition

Mannitol  a nonreabsorbable sugar alcohol  filtered by glomerulus but not reabsorbed by the proximal tubule → osmotic diuresis  half-life : 1 to 36hr (may be retained in renal failure)  preferential water diuresis → water defecit, Hypernatremia, plasma osmolarity ↑  treatment of cerebral edema, elevated ICP

Loop diuretics Harrison's Principles of Internal Medicine, 18th edition  the most potent diuretics (lead to the excretion of up to 20~25% of filtered Na)  furosemide, bumetanide, torsemide, ethacrynic acid (Sulfonamide derivatives except for ethacrynic acid)  Inhibits the Na-K-2Cl cotransporter (compete for the chloride site on this carrier)  reabsorption of Ca in the loop of Henle : passive, driven by the electrochemical gradient created by NaCl transport, paracellular pathway  → increase Ca excretion : treatment of hypercalcemia

 highly protein bound (≥95%) → limits the drug to the vascular space, maximizes its rate of delivery to the kidney : enter the tubular lumen by secretion in the proximal tubule, not by glomerular filtration  furosemide : Bioavailability of oral preparetion is about 50% (interpatient and intapatient variability, range 10~100%) → dose should be doubled for oral furosemide ※ vs. torsemide, bumetanide : 80~100%  torsemide : has a longer half-life than both furosemide and bumetanide Loop diuretics Am J Physiol Renal Physiol 2003;284:F11–F21

Loop diuretics  No diuresis seen until a threshold rate of drug excretion is attained : If a patient does not respond to 40mg of furosemide, the single dose should be increased to 60 or 80mg, rather than giving the same dose twice a day  Maximum effective dose (ceiling dose) : a plateau is reached in which even higher doses produce no further diuresis N Engl J Med 1998;339:

 The maximum effective diuretic dose is higher in patients with heart failure, cirrhosis, or renal failure : d/t decreased renal perfusion (and therefore decreased drug delivery to the kidney), diminished proximal secretion (d/t the retention of competing anions in renal failure), renal vasoconstriction(cirrhosis), and enhanced activity of sodium-retaining forces (such as the RAAS) Loop diuretics N Engl J Med 1998;339:

 Diuresis-related : hypokalemia, metabolic alkalosis, signs of decreased tissue perfusion (hypotension, BUN ↑, Cr ↑, hyperuricemia, hyponatremia)  Hypersensitivity reaction  rash, acute interstitial nephritis(rarely)  similar to those produced by other sulfonamide drugs  Ototoxicity  inhibition of an isoform of this cotransporter in the inner ear  decreased hearing, tinnitus, deafness(may be permanent)  occur with high-dose IV therapy Loop diuretics

 High salt intake : 24 hour urine Na > 100meq/day → adequate diuretic response & high salt intake  Infusion with albumin  administration of 40 to 80 mg of furosemide added to 6.25 to 12.5 g of salt-poor albumin  increasing diuretic delivery to the kidney by keeping furosemide within the vascular space  But, lack of efficacy..  Posture : supine position  Renal perfusion ↑ → urinary diuretic delivery ↑  Upright position : increases in plasma norepinephrine, renin, aldosterone Refractory to loop diuretics

Infusion with albumin 60mg of furosemide + 200mL of a 20% albumin solution a modest increase in sodium excretion without an increase in the rate of furosemide excretion 40mg of furosemide + 25g of albumin not increase the rate of either furosemide or sodium excretion J Am Soc Nephrol 2001;12:1010–1016 Kidney Int 1999;55:629-34

 continuous infusion  safer (less ototoxicity) and more effective than bolus injections  maintenance of an effective rate of drug excretion  bolus therapy results in higher initial serum concentrations and higher initial rates of urinary diuretic excretion than a continuous infusion ☞ continuous infusion should not be tried in patients who have not responded to the maximum bolus doses  Regimen - renal insufficiency : initial furosemide infusion rate of 20mg/h, higher of 40 mg/h - reasonable renal function : initial infusion rate of 5mg/h, higher of 10 mg/h  The literature has reports of higher infusion rates of up to 240 mg/h But, ototoxicity and other side effects → the addition of a thiazide-type diuretic or fluid removal via ultrafltration Refractory to loop diuretics

Diuretic tolerance  a decrease in the response to a diuretic after the first dose  Short-term tolerance  initial reduction in extracellular fluid volume → decline in the drug level in plasma and tubular fluid to below the diuretic threshold  activation of the RAAS and the sympathetic nervous system  Long-term tolerance (diuretic braking phenomenon)  activation of the RAAS → circulating angiotensin II ↑ → promotes increased proximal sodium reabsorption  the up-regulation of sodium transporters downstream from the primary site of diuretic action  structural hypertrophy of distal nephron segments  Sodium restriction, repeated or higher doses, combinations of diuretics

Thiazide diuretics Harrison's Principles of Internal Medicine, 18th edition  hydrochlorothiazide, indapamide, chlorothiazide, chlorothalidon, metolazone  Inhibits the Na-Cl cotransporter  smaller natriuretic effect than loop diuretics (inhibit the reabsorption of 3~5% of filtered Na)  First-line agents in the treatment of hypertension : proven to reduce cardiovascular mortality and morbidity in systolic and diastolic forms of hypertension

 ineffective at GFR <30ml/min  Metolazone : efficacy in patients who have renal insufficiency  The distal tubule is the major site of active Ca reabsorption : thiazides increase the reabsorption of Ca → treatment of recurrent kidney stones d/t hypercalciuria Thiazide diuretics

Potassium-sparing diuretics  act in the principal cells in the cortical collecting tubule  amiloride, triamterene : epithelial sodium-channel (ENaC) blocker  spironolactone and eplerenone : mineralocorticoid receptor → primary aldosteronism, heart failure, cirrhosis  weak natriuretic activity  hyperkalemia and metabolic acidosis Harrison's Principles of Internal Medicine, 18th edition

 Trimethoprim : can act as a potassium-sparing diuretic when given in high doses → nephrotoxicity, hyperkalemia  Eplerenone : more selective for aldosterone less endocrine side effects (eg, gynecomastia, menstrual abnormalities, impotence, and decreased libido) Potassium-sparing diuretics

 Edema = a palpable swelling produced by expansion of the interstitial fluid volume  massive and generalized → anasarca  heart failure, cirrhosis, and the nephrotic syndrome, renal failure as well as local conditions (venous and lymphatic disease)  When diuretics are administered, the fluid that is lost initially comes from the intravascular space → venous pressure and capillary hydraulic pressure ↓ → restoration of the plasma volume by the mobilization of edema fluid into the vascular space Treatment of edema

 In heart failure or nephrotic syndrome : since most capillary beds are involved, the edema fluid can be mobilized rapidly → removal of ≥ 2~3L of edema fluid in 24 hours  But, cirrhosis - ascites and no peripheral edema : the excess ascitic fluid can only be mobilized via the peritoneal capillaries → 300~500mL/day is the maximum amount that can be mobilized by most patients  If the diuresis proceeds more rapidly, the ascitic fluid will be unable to completely replenish the plasma volume → resulting in azotemia and possible precipitation of the hepatorenal syndrome

 In venous insufficiency, lymphedema, or ascites due to peritoneal malignancy “ fluid removal → reduction in venous and intracapillary pressure → edema fluid to be mobilized and the plasma volume to be maintained ” ☞ not occurred  So, diuretics should be used with caution and monitoring of the serum creatinine monitored in such patients  The mainstays of therapy of lower extremity edema d/t venous insufficiency : leg elevation well-fitted, knee-high compression stockings Treatment of edema

 Evaluation and optimization of volume status is an essential component of treatment in patients with HF  In contrast to ACEi, beta blockers, and aldosterone antagonist, limited outcomes data are available for diuretic therapy  3 major manifestations of volume overload : pulmonary congestion, pph edema, and elevated JVP  combination of an oral loop diuretic and low sodium diet Use of diuretics in heart failure

 IV administration of loop diuretics is generally required for acute decompensation or severe disease  decreased intestinal perfusion  reduced intestinal motility  mucosal edema reduce the rate of diuretic absorption  bolus vs. continuous infusion high dose vs. low dose Use of diuretics in heart failure

 308 pts with acute decompensated heart failure  prospective, double-blind, randomized trial  bolus every 12 hours or continuous infusion  low dose (equivalent to the patient’s previous oral dose) or high dose (2.5 times the previous oral dose)

 Daily assessment of patient weight - the most effective method for documenting effective diuresis : use the same scale, performed at the same time each day (in the morning, prior to eating, after voiding)  decrease in intracardiac filling pressure induced by the diuresis → lower the cardiac output → reduced tissue perfusion → unexplained rise in serum Cr (reflects a reduction in GFR) : worse prognosis  IV furosemide in acute pulmonary edema  venodilatory effect → cardiac filling pr ↓ → pulmonary congestion ↓  renal production of PG ↑ Use of diuretics in heart failure

Reference  N Engl J Med 2009;361:  N Engl J Med 1998;339:  Am J Physiol Renal Physiol 2003;284:F11-F21  N Engl J Med 2011;364:  Crit Care Med 2008;36[Suppl.]:S89-S94  Clin J Am Soc Nephrol 2010;5:  J Clin Hypertens 2011;13:  J Am Soc Nephrol 2001;12:1010–1016  Kidney Int 1999;55:  Korean J Med 2011;80:8-14  Harrison's Principles of Internal Medicine, 18th edition 